United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++ ) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++ ) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 10 mg in 1 ml - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block and myocardial damage.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++ ) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++ ) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. parenteral administration of the drug is contraindi

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; glucose monohydrate, quantity: 25 g/l (equivalent: glucose, qty 22.7 g/l); calcium chloride dihydrate, quantity: 0.184 g/l; sodium chloride, quantity: 5.38 g/l - solution, dialysis - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - icodextrin, quantity: 75 g/l; sodium chloride, quantity: 5.4 g/l; sodium lactate, quantity: 4.5 g/l; calcium chloride dihydrate, quantity: 257 mg/l; magnesium chloride hexahydrate, quantity: 51 mg/l - solution, dialysis - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - indicated as "an alternative osmotic agent in dialysis solution for the long dwell exchange in patients treated with peritoneal dialysis."

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - icodextrin, quantity: 75 g/l; sodium chloride, quantity: 5.4 g/l; sodium lactate, quantity: 4.5 g/l; calcium chloride dihydrate, quantity: 257 mg/l; magnesium chloride hexahydrate, quantity: 51 mg/l - solution, dialysis - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - indicated as "an alternative osmotic agent in dialysis solution for the long dwell exchange in patients treated with peritoneal dialysis."

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - sodium chloride, quantity: 5.38 g/l; calcium chloride dihydrate, quantity: 0.183 g/l; magnesium chloride hexahydrate, quantity: 0.0508 g/l; sodium lactate, quantity: 4.48 g/l; glucose monohydrate, quantity: 5.5 g/l - solution, irrigation - excipient ingredients: sodium hydroxide; water for injections - use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis.

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - sodium chloride, quantity: 5.39 g/l; calcium chloride dihydrate, quantity: 0.183 g/l; magnesium chloride hexahydrate, quantity: 0.0508 g/l; sodium lactate, quantity: 4.48 g/l; glucose monohydrate, quantity: 5.5 g/l - solution, dialysis - excipient ingredients: sodium hydroxide; water for injections - indications: use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 4.25 g/l; sodium chloride, quantity: 5.38 g/l; sodium lactate, quantity: 4.48 g/l; calcium chloride dihydrate, quantity: 257 mg/l; magnesium chloride hexahydrate, quantity: 50.8 mg/l - solution, irrigation - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - dianeal low calcium peritoneal dialysis solution is indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis or intermittent peritoneal dialysis and/or automated peritoneal dialysis and can also be used for acute renal failure.